ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment.

Using current resources, ABIONYX plans to advance activities with existing development assets inherited from Cerenis. ABIONYX is also exploring joint activities with a number of attractive partners.

 
Beginning on 29 August 2019 : 

- Share name: ABIONYX Pharma (replacing CERENIS Therapeutics) 

- ISIN code of the share: FR0012616852 (unchanged)

- Stock symbol / Mnemonic code of the action: ABNX (replacing CEREN).  

Contribute to the development of innovative therapies for patients without existing or effective treatment

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment

The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology , more specifically in immuno oncology and chemotherapy